{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:43:19Z","timestamp":1790203399107,"version":"4.1.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Writer Fund"},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatment, and structured patient care. This requires intensive collaboration across several disciplines, and between resident physicians and specialized centers. The aim of this consensus statement is to provide guidance for the rapid and efficient diagnosis and treatment of light-chain amyloidosis and transthyretin amyloidosis, which are the most common forms of cardiac amyloidosis.<\/jats:p>","DOI":"10.1007\/s00508-020-01781-z","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T14:02:46Z","timestamp":1607004166000},"page":"742-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement"],"prefix":"10.1007","volume":"132","author":[{"given":"Diana","family":"Bonderman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"P\u00f6lzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ablasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aschauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Auer-Grumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"D\u00f6rler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kammerlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Koschutnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Stephan","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Reiter-Malmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Michael","family":"Zaruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Badr Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fclsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mascherbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"1781_CR1","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini\u00a0G, et al. Serum N\u2011terminal pro-brain natriuretic peptide is a\u00a0sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440\u20135.","journal-title":"Circulation"},{"key":"1781_CR2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk\u00a0RH, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J\u00a0Am Coll Cardiol. 2016;68:1323\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR3","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2174\/0929867325666180104153338","volume":"26","author":"K Ablasser","year":"2019","unstructured":"Ablasser\u00a0K, et\u00a0al. Unfolding cardiac amyloidosis\u2014from pathophysiology to cure. Curr Med Chem. 2019;26:2865\u201378.","journal-title":"Curr Med Chem"},{"key":"1781_CR4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen\u00a0M, et al. Senile systemic amyloidosis affects 25\u202f% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a\u00a0population-based autopsy study. Ann Med. 2008;40:232\u20139.","journal-title":"Ann Med"},{"key":"1781_CR5","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez\u00a0E, et al. Wild-type transthyretin amyloidosis as a\u00a0cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"1781_CR6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","volume":"71","author":"PR Scully","year":"2018","unstructured":"Scully\u00a0PR, et\u00a0al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J\u00a0Am Coll Cardiol. 2018;71:463\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","volume":"19","author":"JL Cavalcante","year":"2017","unstructured":"Cavalcante\u00a0JL, et\u00a0al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J\u00a0Cardiovasc Magn Reson. 2017;19:98.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1781_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle\u00a0RA, et\u00a0al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"1781_CR9","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","volume":"22","author":"C Nitsche","year":"2020","unstructured":"Nitsche C, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22:1852\u20131862. https:\/\/doi.org\/10.1002\/ejhf.1756.","journal-title":"Eur J Heart Fail"},{"key":"1781_CR10","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle\u00a0J, et\u00a0al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J\u00a0Am Coll Cardiol. 2019;74:2638\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR11","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar\u00a0AD, et\u00a0al. A European collaborative study of treatment outcomes in 346\u00a0patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420\u20137.","journal-title":"Blood"},{"key":"1781_CR12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2015-11-681650","volume":"127","author":"BM Weiss","year":"2016","unstructured":"Weiss\u00a0BM, et\u00a0al. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016;127:2275\u201380.","journal-title":"Blood"},{"key":"1781_CR13","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle\u00a0RA, et\u00a0al. Primary systemic amyloidosis: clinical and laboratory features in 474\u00a0cases. Semin Hematol. 1995;32:45\u201359.","journal-title":"Semin Hematol"},{"key":"1781_CR14","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini\u00a0G, et\u00a0al. Amyloidosis: pathogenesis and new therapeutic options. J\u00a0Clin Oncol. 2011;29:1924\u201333.","journal-title":"J Clin Oncol"},{"key":"1781_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney\u00a0JH, et\u00a0al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525\u201332.","journal-title":"Br J Haematol"},{"key":"1781_CR16","first-page":"127","volume":"47","author":"DR Jacobson","year":"1990","unstructured":"Jacobson\u00a0DR, et al. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a\u00a0late-onset disease of genetic etiology. Am J Hum Genet. 1990;47:127\u201336.","journal-title":"Am J Hum Genet"},{"key":"1781_CR17","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2006.01.042","volume":"47","author":"J Buxbaum","year":"2006","unstructured":"Buxbaum\u00a0J, et\u00a0al. Transthyretin V122I in African Americans with congestive heart failure. J\u00a0Am Coll Cardiol. 2006;47:1724\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","volume":"28","author":"OK Siddiqi","year":"2018","unstructured":"Siddiqi\u00a0OK, et\u00a0al. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10\u201321.","journal-title":"Trends Cardiovasc Med"},{"key":"1781_CR19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry\u00a0BW, et\u00a0al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J\u00a0Am Coll Cardiol. 2018;72:2040\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","volume":"165","author":"B Ng","year":"2005","unstructured":"Ng\u00a0B, et al. Senile systemic amyloidosis presenting with heart failure: a\u00a0comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425\u20139.","journal-title":"Arch Intern Med"},{"key":"1781_CR21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan\u00a0M, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a\u00a0novel staging system. J\u00a0Am Coll Cardiol. 2016;68:1014\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed\u00a0SF, et\u00a0al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113\u201322.","journal-title":"JACC Heart Fail"},{"key":"1781_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/CIRCULATIONAHA.115.020351","volume":"133","author":"PP Liu","year":"2016","unstructured":"Liu\u00a0PP, et al. Wild-type transthyretin amyloid cardiomyopathy: a missed cause of heart failure with preserved ejection fraction with evolving treatment implications. Circulation. 2016;133:245\u20137.","journal-title":"Circulation"},{"key":"1781_CR24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehv328","volume":"36","author":"A Castano","year":"2015","unstructured":"Castano\u00a0A, et al. Unveiling wild-type transthyretin cardiac amyloidosis as a\u00a0significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J. 2015;36:2595\u20137.","journal-title":"Eur Heart J"},{"key":"1781_CR25","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","volume":"37","author":"A Galat","year":"2016","unstructured":"Galat\u00a0A, et\u00a0al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart\u00a0J. 2016;37:3525\u201331.","journal-title":"Eur Heart J"},{"key":"1781_CR26","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz\u00a0MA, et\u00a0al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J\u00a0Am Coll Cardiol. 2015;66:2451\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR27","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney\u00a0JH, et\u00a0al. Senile systemic amyloidosis: clinical features at presentation and outcome. J\u00a0Am Heart Assoc. 2013;2:e98.","journal-title":"J Am Heart Assoc"},{"key":"1781_CR28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini\u00a0G, et\u00a0al. Molecular mechanisms of amyloidosis. N\u00a0Engl J Med. 2003;349:583\u201396.","journal-title":"N Engl J Med"},{"key":"1781_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/13506129.2010.526812","volume":"17","author":"JD Sipe","year":"2010","unstructured":"Sipe\u00a0JD, et\u00a0al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17:101\u20134.","journal-title":"Amyloid"},{"key":"1781_CR30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini\u00a0G, et\u00a0al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.","journal-title":"Nat Rev Dis Primers"},{"key":"1781_CR31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","volume":"12","author":"MA Gertz","year":"2015","unstructured":"Gertz\u00a0MA, et\u00a0al. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12:91\u2013102.","journal-title":"Nat Rev Cardiol"},{"key":"1781_CR32","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi\u00a0J, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a\u00a0non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S\u00a0A. 2010;107:4188\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1781_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.7754382","volume":"268","author":"HL Monaco","year":"1995","unstructured":"Monaco\u00a0HL, et al. Structure of a\u00a0complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268:1039\u201341.","journal-title":"Science"},{"key":"1781_CR34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jcp.2004.017293","volume":"58","author":"I Kholova","year":"2005","unstructured":"Kholova\u00a0I, et\u00a0al. Amyloid in the cardiovascular system: a\u00a0review. J\u00a0Clin Pathol. 2005;58:125\u201333.","journal-title":"J Clin Pathol"},{"key":"1781_CR35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-291X(85)91956-4","volume":"129","author":"MR Wallace","year":"1985","unstructured":"Wallace\u00a0MR, et\u00a0al. Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun. 1985;129:753\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1781_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando\u00a0Y, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"key":"1781_CR37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/anr.1780321119","volume":"32","author":"N Harats","year":"1989","unstructured":"Harats\u00a0N, et\u00a0al. Hereditary amyloidosis: evidence against early amyloid deposition. Arthritis Rheum. 1989;32:1474\u20136.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1781_CR38","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3390\/jcm9072234","volume":"9","author":"M Auer-Grumbach","year":"2020","unstructured":"Auer-Grumbach M, et al. Hereditary ATTR amyloidosis in Austria: prevalence and epidemiological hot spots. J\u00a0Clin Med. 2020;9(7):2234. https:\/\/doi.org\/10.3390\/jcm9072234.","journal-title":"J\u00a0Clin Med."},{"key":"1781_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJ Saraiva","year":"2001","unstructured":"Saraiva\u00a0MJ. Transthyretin amyloidosis: a\u00a0tale of weak interactions. FEBS Lett. 2001;498:201\u20133.","journal-title":"FEBS Lett"},{"key":"1781_CR40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.2224","volume":"213","author":"SD Santos","year":"2007","unstructured":"Santos\u00a0SD, et al. Impairment of the ubiquitin-proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. J\u00a0Pathol. 2007;213:200\u20139.","journal-title":"J Pathol"},{"key":"1781_CR41","doi-asserted-by":"crossref","first-page":"e0125392","DOI":"10.1371\/journal.pone.0125392","volume":"10","author":"G da Costa","year":"2015","unstructured":"da Costa\u00a0G, et\u00a0al. Transthyretin Amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease. PLoS ONE. 2015;10:e125392.","journal-title":"PLoS ONE"},{"key":"1781_CR42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.110.010447","volume":"124","author":"RH Falk","year":"2011","unstructured":"Falk\u00a0RH. Cardiac amyloidosis: a\u00a0treatable disease, often overlooked. Circulation. 2011;124:1079\u201385.","journal-title":"Circulation"},{"key":"1781_CR43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/heart.88.6.615","volume":"88","author":"L Bernardi","year":"2002","unstructured":"Bernardi\u00a0L, et\u00a0al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a\u00a0compensatory role against postural hypotension? Heart. 2002;88:615\u201321.","journal-title":"Heart"},{"key":"1781_CR44","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonzalez-Lopez","year":"2017","unstructured":"Gonzalez-Lopez\u00a0E, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart\u00a0J. 2017;38:1895\u2013904.","journal-title":"Eur Heart J"},{"key":"1781_CR45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","volume":"109","author":"F Escher","year":"2020","unstructured":"Escher\u00a0F, et\u00a0al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109:78\u201388.","journal-title":"Clin Res Cardiol"},{"key":"1781_CR46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","volume":"103","author":"M Grogan","year":"2017","unstructured":"Grogan\u00a0M, et al. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103:1065\u201372.","journal-title":"Heart"},{"key":"1781_CR47","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller\u00a0HI, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA. 2017;318:962\u20133.","journal-title":"JAMA"},{"key":"1781_CR48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki\u00a0PL, et al. Hereditary ATTR amyloidosis: a\u00a0single-institution experience with 266\u00a0patients. Amyloid. 2015;22:123\u201331.","journal-title":"Amyloid"},{"key":"1781_CR49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.34.8.1025","volume":"34","author":"G Said","year":"1984","unstructured":"Said\u00a0G, et al. Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: a\u00a0clinicopathologic study. Neurology. 1984;34:1025\u201332.","journal-title":"Neurology"},{"key":"1781_CR50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles\u00a0RM, et\u00a0al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7:709\u201316.","journal-title":"JACC Heart Fail"},{"key":"1781_CR51","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","volume":"129","author":"CC Quarta","year":"2014","unstructured":"Quarta\u00a0CC, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129:1840\u20139.","journal-title":"Circulation"},{"key":"1781_CR52","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi\u00a0C, et\u00a0al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203\u201312.","journal-title":"Circulation"},{"key":"1781_CR53","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","volume":"114","author":"NB Cyrille","year":"2014","unstructured":"Cyrille\u00a0NB, et\u00a0al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114:1089\u201393.","journal-title":"Am J Cardiol"},{"key":"1781_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/anec.12032","volume":"18","author":"M Boldrini","year":"2013","unstructured":"Boldrini\u00a0M, et\u00a0al. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013;18:327\u201335.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"1781_CR55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang\u00a0RM, et\u00a0al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR56","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan\u00a0D, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442\u20138.","journal-title":"Heart"},{"key":"1781_CR57","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","volume":"18","author":"F Salinaro","year":"2017","unstructured":"Salinaro\u00a0F, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017;18:1057\u201364.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR58","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","volume":"10","author":"ED Pagourelias","year":"2017","unstructured":"Pagourelias\u00a0ED, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10:e5588.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1781_CR59","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1540-8175.2010.01238.x","volume":"27","author":"RN Belkin","year":"2010","unstructured":"Belkin\u00a0RN, et al. A novel two-dimensional echocardiographic finding in cardiac amyloidosis. Echocardiography. 2010;27:1171\u20136.","journal-title":"Echocardiography"},{"key":"1781_CR60","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1253\/circj.CJ-14-1328","volume":"79","author":"GY Lee","year":"2015","unstructured":"Lee\u00a0GY, et\u00a0al. Visual assessment of relative apical sparing pattern is more useful than quantitative assessment for diagnosing cardiac amyloidosis in borderline or mildly increased left ventricular wall thickness. Circ\u00a0J. 2015;79:1575\u201384.","journal-title":"Circ J"},{"key":"1781_CR61","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","volume":"6","author":"D Liu","year":"2013","unstructured":"Liu\u00a0D, et\u00a0al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:1066\u201372.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1781_CR62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","volume":"60","author":"SJ Buss","year":"2012","unstructured":"Buss\u00a0SJ, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J\u00a0Am Coll Cardiol. 2012;60:1067\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR63","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ehjci\/jey225","volume":"20","author":"C Binder","year":"2019","unstructured":"Binder\u00a0C, et\u00a0al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2019;20:512\u201324.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","volume":"9","author":"J Ternacle","year":"2016","unstructured":"Ternacle\u00a0J, et\u00a0al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain Echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:126\u201338.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcmg.2009.11.013","volume":"3","author":"J Koyama","year":"2010","unstructured":"Koyama\u00a0J, et al. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3:333\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR66","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","volume":"17","author":"SF Nagueh","year":"2016","unstructured":"Nagueh\u00a0SF, et\u00a0al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321\u201360.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR67","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/eurheartj\/ehi040","volume":"26","author":"KM Modesto","year":"2005","unstructured":"Modesto\u00a0KM, et\u00a0al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart\u00a0J. 2005;26:173\u20139.","journal-title":"Eur Heart J"},{"key":"1781_CR68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ejechocard\/jer289","volume":"13","author":"F Cappelli","year":"2012","unstructured":"Cappelli\u00a0F, et\u00a0al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012;13:416\u201322.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR69","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1253\/circj.CJ-16-0364","volume":"80","author":"C de Gregorio","year":"2016","unstructured":"de Gregorio\u00a0C, et\u00a0al. Left atrial morphology, size and function in patients with transthyretin cardiac amyloidosis and primary hypertrophic cardiomyopathy\u2014comparative strain imaging study. Circ\u00a0J. 2016;80:1830\u20137.","journal-title":"Circ J"},{"key":"1781_CR70","first-page":"1128","volume":"18","author":"K Nochioka","year":"2017","unstructured":"Nochioka\u00a0K, et\u00a0al. Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017;18:1128\u201337.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR71","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ehjci\/jes009","volume":"13","author":"D Bellavia","year":"2012","unstructured":"Bellavia\u00a0D, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a\u00a05-year cohort study. Eur Heart J Cardiovasc Imaging. 2012;13:680\u20139.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/13506129.2016.1194264","volume":"23","author":"D Bodez","year":"2016","unstructured":"Bodez\u00a0D, et\u00a0al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016;23:158\u201367.","journal-title":"Amyloid"},{"key":"1781_CR73","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ehj.2004.06.040","volume":"25","author":"DJ Pennell","year":"2004","unstructured":"Pennell\u00a0DJ, et\u00a0al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart\u00a0J. 2004;25:1940\u201365.","journal-title":"Eur Heart J"},{"key":"1781_CR74","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","volume":"12","author":"M Fontana","year":"2019","unstructured":"Fontana\u00a0M, et\u00a0al. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12:2345\u201356.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro\u00a0A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J\u00a0Am Coll Cardiol. 2017;70:466\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ehjci\/jew130","volume":"17","author":"D Bonderman","year":"2016","unstructured":"Bonderman\u00a0D, et al. Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology. Eur Heart J Cardiovasc Imaging. 2016;17:978\u201380.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1781_CR77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1532-429X-14-63","volume":"14","author":"P Kellman","year":"2012","unstructured":"Kellman\u00a0P, et\u00a0al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J\u00a0Cardiovasc Magn Reson. 2012;14:63.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1781_CR78","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro\u00a0A, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12:810\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR79","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jcmg.2018.06.010","volume":"11","author":"F Duca","year":"2018","unstructured":"Duca\u00a0F, et\u00a0al. Cardiac magnetic resonance T1 mapping in cardiac amyloidosis. JACC Cardiovasc Imaging. 2018;11:1924\u20136.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR80","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","volume":"6","author":"TD Karamitsos","year":"2013","unstructured":"Karamitsos\u00a0TD, et\u00a0al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6:488\u201397.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana\u00a0M, et\u00a0al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157\u201365.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1781_CR82","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","volume":"277","author":"M Fontana","year":"2015","unstructured":"Fontana\u00a0M, et al. Differential Myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology. 2015;277:388\u201397.","journal-title":"Radiology"},{"key":"1781_CR83","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","volume":"6","author":"SM Banypersad","year":"2013","unstructured":"Banypersad\u00a0SM, et\u00a0al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34\u20139.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1781_CR84","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","volume":"6","author":"DM Sado","year":"2013","unstructured":"Sado\u00a0DM, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392\u20138.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1781_CR85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli\u00a0DR, et\u00a0al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J\u00a0Cardiovasc Magn Reson. 2017;19:75.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1781_CR86","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz\u00a0MA, et\u00a0al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a\u00a0consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"1781_CR87","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar\u00a0S, et\u00a0al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J\u00a0Clin Oncol. 2012;30:989\u201395.","journal-title":"J Clin Oncol"},{"key":"1781_CR88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","volume":"5","author":"S Takashio","year":"2018","unstructured":"Takashio\u00a0S, et\u00a0al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018;5:27\u201335.","journal-title":"ESC Heart Fail"},{"key":"1781_CR89","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini\u00a0E, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc\u20113,3\u2011diphosphono\u20111,2\u2011propanodicarboxylic acid scintigraphy. J\u00a0Am Coll Cardiol. 2005;46:1076\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","volume":"38","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi\u00a0C, et al. Usefulness and limitations of 99mTc\u20113,3\u2011diphosphono\u20111,2\u2011propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1781_CR91","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore\u00a0JD, et\u00a0al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312.","journal-title":"Circulation"},{"key":"1781_CR92","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","volume":"45","author":"G Treglia","year":"2018","unstructured":"Treglia\u00a0G, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a\u00a0bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45:1945\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1781_CR93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5858\/2001-125-0250-CR","volume":"125","author":"DP Steensma","year":"2001","unstructured":"Steensma\u00a0DP. \u201cCongo\u201d red: out of Africa? Arch Pathol Lab Med. 2001;125:250\u20132.","journal-title":"Arch Pathol Lab Med"},{"key":"1781_CR94","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","volume":"106","author":"D Mohty","year":"2013","unstructured":"Mohty\u00a0D, et\u00a0al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106:528\u201340.","journal-title":"Arch Cardiovasc Dis"},{"key":"1781_CR95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","volume":"68","author":"AV Kristen","year":"2016","unstructured":"Kristen\u00a0AV, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J\u00a0Am Coll Cardiol. 2016;68:13\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR96","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2011.0296","volume":"86","author":"AM From","year":"2011","unstructured":"From\u00a0AM, et\u00a0al. Current status of endomyocardial biopsy. Mayo Clin Proc. 2011;86:1095\u2013102.","journal-title":"Mayo Clin Proc"},{"key":"1781_CR97","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk\u00a0RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047\u201360.","journal-title":"Circulation"},{"key":"1781_CR98","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","volume":"113","author":"NM Fine","year":"2014","unstructured":"Fine\u00a0NM, et\u00a0al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113:1723\u20137.","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"1781_CR99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/13506129.2012.665400","volume":"19","author":"SR Zeldenrust","year":"2012","unstructured":"Zeldenrust\u00a0SR. Genotype--phenotype correlation in FAP. Amyloid. 2012;19(Suppl 1):22\u20134.","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"1781_CR100","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici\u00a0L, et\u00a0al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27\u2013S35.","journal-title":"Curr Opin Neurol"},{"key":"1781_CR101","first-page":"1993","volume-title":"GeneReviews","author":"YK Sekijima","year":"2012","unstructured":"Sekijima\u00a0YK, Tokuda\u00a0T, et\u00a0al. Familial transthyretin amyloidosis 2001 Nov 5 [updated 2012 Jan 26]. In: Pagon\u00a0RA, Adam\u00a0MP, Ardinger\u00a0HH, et\u00a0al., editors. GeneReviews. Seattle: University of Washington; pp.\u00a01993\u20132017."},{"key":"1781_CR102","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore\u00a0JD, et\u00a0al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart\u00a0J. 2018;39:2799\u2013806.","journal-title":"Eur Heart J"},{"key":"1781_CR103","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","volume":"104","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri\u00a0A, et al. Prognostication of survival using cardiac troponins and N\u2011terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881\u20137.","journal-title":"Blood"},{"key":"1781_CR104","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.recesp.2017.05.018","volume":"70","author":"E Gonzalez-Lopez","year":"2017","unstructured":"Gonzalez-Lopez\u00a0E, et al. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol. 2017;70:991\u20131004.","journal-title":"Rev Esp Cardiol"},{"key":"1781_CR105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","volume":"24","author":"F Aus dem Siepen","year":"2017","unstructured":"Aus dem Siepen\u00a0F, et\u00a0al. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017;24:132\u20133.","journal-title":"Amyloid"},{"key":"1781_CR106","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","volume":"63","author":"A Rubinow","year":"1981","unstructured":"Rubinow\u00a0A, et\u00a0al. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285\u20138.","journal-title":"Circulation"},{"key":"1781_CR107","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng\u00a0D, et\u00a0al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420\u20136.","journal-title":"Circulation"},{"key":"1781_CR108","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","volume":"73","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro\u00a0A, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J\u00a0Am Coll Cardiol. 2019;73:1733\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR109","first-page":"303","volume":"3","author":"PS Dardas","year":"2002","unstructured":"Dardas\u00a0PS, et\u00a0al. Echocardiographic evidence of atrial myopathy in amyloidosis: a\u00a0case report. Eur J Echocardiogr. 2002;3:303\u20135.","journal-title":"Eur J Echocardiogr"},{"key":"1781_CR110","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","volume":"124","author":"P Kapoor","year":"2011","unstructured":"Kapoor\u00a0P, et\u00a0al. Cardiac amyloidosis: a\u00a0practical approach to diagnosis and management. Am J Med. 2011;124:1006\u201315.","journal-title":"Am J Med"},{"key":"1781_CR111","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM197911083011907","volume":"301","author":"PR Greipp","year":"1979","unstructured":"Greipp\u00a0PR, et\u00a0al. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N\u00a0Engl J Med. 1979;301:1050\u20131.","journal-title":"N Engl J Med"},{"key":"1781_CR112","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, et\u00a0al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1781_CR113","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.19102\/icrm.2018.090301","volume":"9","author":"RM John","year":"2018","unstructured":"John\u00a0RM. Arrhythmias in cardiac amyloidosis. J\u00a0Innov Card Rhythm Manag. 2018;9:3051\u20137.","journal-title":"J Innov Card Rhythm Manag"},{"key":"1781_CR114","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","volume":"30","author":"J Reisinger","year":"1997","unstructured":"Reisinger\u00a0J, et\u00a0al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J\u00a0Am Coll Cardiol. 1997;30:1046\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1781_CR115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","volume":"13","author":"CR Barbhaiya","year":"2016","unstructured":"Barbhaiya\u00a0CR, et\u00a0al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13:383\u201390.","journal-title":"Heart Rhythm"},{"key":"1781_CR116","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","volume":"9","author":"RC Givens","year":"2013","unstructured":"Givens\u00a0RC, et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9:229\u201335.","journal-title":"Aging Health"},{"key":"1781_CR117","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","volume":"36","author":"RH Sayed","year":"2015","unstructured":"Sayed\u00a0RH, et\u00a0al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart\u00a0J. 2015;36:1098\u2013105.","journal-title":"Eur Heart J"},{"key":"1781_CR118","first-page":"e382","volume":"140","author":"FM Kusumoto","year":"2019","unstructured":"Kusumoto\u00a0FM, et\u00a0al. 2018 ACC\/AHA\/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140:e382\u2013e482.","journal-title":"Circulation"},{"key":"1781_CR119","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","volume":"30","author":"E Donnellan","year":"2019","unstructured":"Donnellan\u00a0E, et\u00a0al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J\u00a0Cardiovasc Electrophysiol. 2019;30:2427\u201332.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1781_CR120","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori\u00a0SG, et\u00a0al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart\u00a0J. 2015;36:2793\u2013867.","journal-title":"Eur Heart J"},{"key":"1781_CR121","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","volume":"27","author":"NY Tan","year":"2016","unstructured":"Tan\u00a0NY, et\u00a0al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J\u00a0Cardiovasc Electrophysiol. 2016;27:1167\u201373.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1781_CR122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","volume":"22","author":"E Donnellan","year":"2020","unstructured":"Donnellan\u00a0E, et\u00a0al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace. 2020;22:259\u201364.","journal-title":"Europace"},{"key":"1781_CR123","unstructured":"Aktuelle Vyndaqel\u00ae-Fachinformation."},{"key":"1781_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho\u00a0T, et\u00a0al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5:1\u201325.","journal-title":"Neurol Ther"},{"key":"1781_CR125","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, et\u00a0al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med"},{"key":"1781_CR126","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso\u00a0FA, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6\u00a0years. Amyloid. 2017;24:194\u2013204.","journal-title":"Amyloid"},{"key":"1781_CR127","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1814074","volume":"380","author":"MS Maurer","year":"2019","unstructured":"Maurer\u00a0MS, et\u00a0al. Tafamidis for transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med. 2019;380:196\u20137.","journal-title":"N Engl J Med"},{"key":"1781_CR128","doi-asserted-by":"crossref","first-page":"O23","DOI":"10.1186\/1750-1172-10-S1-O23","volume":"10","author":"CC Quarta","year":"2015","unstructured":"Quarta\u00a0CC, et\u00a0al. Diflunisal therapy for cardiac ATTR amyloidosis: a\u00a0longitudinal, prospective, single centre study. Orphanet J Rare Dis. 2015;10:O23\u2013O23.","journal-title":"Orphanet J Rare Dis"},{"key":"1781_CR129","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk\u00a0JL, et\u00a0al. Repurposing diflunisal for familial amyloid polyneuropathy: a\u00a0randomized clinical trial. JAMA. 2013;310:2658\u201367.","journal-title":"JAMA"},{"key":"1781_CR130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Y Sekijima","year":"2015","unstructured":"Sekijima\u00a0Y, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22:79\u201383.","journal-title":"Amyloid"},{"key":"1781_CR131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, et\u00a0al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"1781_CR132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, et\u00a0al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"1781_CR133","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated Amyloidosis. Circulation. 2019;139:431\u201343.","journal-title":"Circulation"},{"key":"1781_CR134","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/13506129.2019.1582490","volume":"26","author":"NR Dasgupta","year":"2019","unstructured":"Dasgupta\u00a0NR, et\u00a0al. Treatment of ATTR cardiomyopathy with a\u00a0TTR specific antisense oligonucleotide, inotersen. Amyloid. 2019;26:20\u20131.","journal-title":"Amyloid"},{"key":"1781_CR135","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini\u00a0G, et\u00a0al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J\u00a0Clin Oncol. 2012;30:4541\u20139.","journal-title":"J Clin Oncol"},{"key":"1781_CR136","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","volume":"33","author":"JP Abeykoon","year":"2019","unstructured":"Abeykoon\u00a0JP, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33:531\u20136.","journal-title":"Leukemia"},{"key":"1781_CR137","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/13506129.2013.853660","volume":"21","author":"T Thenappan","year":"2014","unstructured":"Thenappan\u00a0T, et\u00a0al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid. 2014;21:120\u20133.","journal-title":"Amyloid"},{"key":"1781_CR138","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","volume":"8","author":"IM Hamour","year":"2008","unstructured":"Hamour\u00a0IM, et\u00a0al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8:1056\u20139.","journal-title":"Am J Transplant"},{"key":"1781_CR139","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","volume":"15","author":"MK Davis","year":"2015","unstructured":"Davis\u00a0MK, et\u00a0al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15:650\u20138.","journal-title":"Am J Transplant"},{"key":"1781_CR140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho\u00a0A, et\u00a0al. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282\u201392.","journal-title":"Liver Transpl"},{"key":"1781_CR141","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13506120903090726","volume":"16","author":"G Drent","year":"2009","unstructured":"Drent\u00a0G, et al. Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. Amyloid. 2009;16:133\u201341.","journal-title":"Amyloid"},{"key":"1781_CR142","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz\u00a0MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93:1169\u201380.","journal-title":"Am J Hematol"},{"key":"1781_CR143","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12181-019-00344-5","volume":"13","author":"A Yilmaz","year":"2019","unstructured":"Yilmaz\u00a0A, et\u00a0al. Diagnostik und Therapie der kardialen Amyloidose. Kardiologe. 2019;13:264\u201391.","journal-title":"Kardiologe"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-020-01781-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T09:08:03Z","timestamp":1618564083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-020-01781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":143,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01781-z","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.\u00a0Bonderman: Speaker fees, congress invitations and research grants: Pfizer, Alnylam, Ionis. G.\u00a0P\u00f6lzl: Speaker fees and congress invitations: Pfizer, Akcea, Alnylam, Takeda. K. Ablasser: Speaker fees: Pfizer. H.\u00a0Agis: Speaker fees: Amgen, Celgene, Janssen, Sanofi; research grants, and membership of advisory boards: Amgen, Celgene, Janssen, Sanofi, Takeda, Janssen. M.\u00a0Auer-Grumbach: fees for presentations at scientific meetings, and for participation in advisory board meetings: Pfizer, Akcea, Alnylam; research grants: Pfizer. C.\u00a0Binder: Speaker fees and congress support: Pfizer. F.\u00a0Duca: Speaker fees and congress support: Bayer, Novartis, Alnylam, Pfizer, AOP; research grants: Austrian Society of Cardiology and Pfizer. R.\u00a0Kain: Speaker fees: \u00f6sterreichisches Amyloidoseregister, MEDahead Gesellschaft f\u00fcr medizinische Information m.b.H. C.\u00a0Nitsche: Speaker fees: Pfizer. N.\u00a0Verheyen: Speaker fees: Alnylam, Akcea und Pfizer, and congress invitation: Pfizer. T.\u00a0Weber: Speaker fees: Pfizer. S.\u00a0Aschauer, J.\u00a0D\u00f6rler, C.\u00a0Ebner, M.\u00a0Hacker, A.\u00a0Kammerlander, M.\u00a0Koschutnik, A.S.\u00a0Kroiss, A.\u00a0Mayr, P.\u00a0Rainer, S.\u00a0Reiter-Malmqvist, M.\u00a0Schneider, R.\u00a0Schwarz, M.M.\u00a0Zaruba, R.\u00a0Badr Eslam, M.\u00a0H\u00fclsmann, and J.\u00a0Mascherbauer declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}